SEC Filing Summary

This filing pertains to Tyra Biosciences, Inc. and reports changes in beneficial ownership. Farallon Capital Partners, L.P. and other related entities and individuals, collectively referred to as "Reporting Persons," have acquired shares in Tyra Biosciences, Inc. The filing details the various entities within the Farallon Capital group that hold these shares, including limited partnerships and limited liability companies. It specifies the principal business office address for all reporting persons as c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111. The filing is made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934. The Reporting Persons acknowledge their responsibility for the completeness and accuracy of the information concerning themselves, but not for that of other entities or persons, except to the extent they have reason to believe it is inaccurate. The filing date is February 20, 2026.